While chemo plus immunotherapy showed a benefit in MS-stable patients, it's not curative. The expert predicts clinicians may shift away from using it universally upfront, potentially favoring other agents first for this non-curative but beneficial therapy.
Even in elderly or frail patients with MSI-high endometrial cancer, the rapid and effective tumor response from combination chemotherapy and immunotherapy often improves quality of life so significantly that it's the preferred approach over single-agent IO.
Conditional survival data from the RUBY trial is highly encouraging. For MSI-high patients, reaching the one-year survival mark implies an 84% chance of long-term survival, which skyrockets to nearly 95% for those who reach the three-year landmark.
Clinicians are far more cautious using immunotherapy in organ transplant recipients than in patients with autoimmune disease. The risk of irreversible graft rejection is a major deterrent, reserving checkpoint inhibitors only for when no other treatment options exist.
The KEYNOTE-B21 adjuvant trial revealed a crucial paradox: adding pembrolizumab may worsen outcomes for mismatch repair proficient (pMMR) patients (HR 1.2), while being highly beneficial for dMMR patients. This highlights that metastatic and adjuvant settings are not equivalent.
Early neoadjuvant trials show that while immunotherapy can eliminate metastatic endometrial cancer, residual disease often persists within the uterus. This suggests the uterus is a protected environment, tempering enthusiasm for omitting hysterectomy even in exceptional responders.
Potent responses to chemo-immunotherapy are promoting a shift toward neoadjuvant treatment for advanced endometrial cancer. Waiting six cycles often achieves a response sufficient to allow for a minimally invasive hysterectomy instead of a more extensive primary debulking surgery.
A common clinical observation is that patients who develop significant immune-related toxicities, like colitis or pneumonitis, are frequently the same ones who experience the most profound and durable responses to checkpoint inhibitor therapy.